L-Arginine in Children Having Sickle Cell Disease With Increased Tricuspid Regurgitant Jet Velocity

Clinical Study to Evaluate the Possible Efficacy and Safety of L-Arginine in Children Having Sickle Cell Disease With Increased Tricuspid Regurgitant Jet Velocity

This study aims to investigate the possible efficacy and safety of L-Arginine in children having Sickle Cell Disease with increased Tricuspid Regurgitant Jet Velocity

Inclusion Criteria:

• children having Sickle Cell Disease with increased Tricuspid Regurgitant Jet Velocity
• age 5-18 years

Exclusion Criteria:

• Another chronic hemolytic anemia.
• Patients with documented causes of pulmonary hypertension other than SCD.
• Allergy to L-arginine.
• Patients with Asthma.
• Hepatic dysfunction: serum Alanine Aminotransferase (ALT) > 3X upper value.
• Renal dysfunction: Creatinine level greater than or equal to 1.2 mg/dl.